Add this topic to your myFT Digest for news straight to your inbox
Virginia-based drugmaker says switch would attract more US investors
Biotech company hopes to win first US approval for medicine aimed at people addicted to marijuana
Companies analysis from our sister publication
The pharmaceuticals company has returned to financial health and is exploring a dual UK-US listing
London-listed drugmaker predicts strong sales growth for opioid use disorder treatments
After years of failure, the maker of drug dependence treatments has been making the right moves
Revenues will be up to 18% higher than originally expected
UK drugmaker stands by payout based on ‘absence of any findings of personal wrongdoing’ in US opioid case
Robinhood plans IPO, Citi launches ‘Zoom-free Fridays’
The Frasers boss is toying with old foe Philip Green; Reckitt is ruthless in pursuit of spin-off Indivior
Claim relates to US settlement over past marketing of opioid addiction treatment Suboxone
Resolution with justice department takes total paid over addiction treatment Suboxone to $2bn
Case against Shaun Thaxter is latest in crackdown by American prosecutors on industry
US charges over opioid addiction treatment could have ‘material impact’ while generics take share
Drugmaker lifted by strong performance of opioid treatment Suboxone
Reckitt Benckiser’s $1.4bn settlement is the largest penalty so far linked to the epidemic
Deal over addiction treatment marketing is largest fine so far in painkiller epidemic
Suboxone drug has been at the centre of a US probe into its marketing
Shares in UK-listed addiction specialist plummeted last month after indictment
Softened demand for cold and flu medicines comes as company braces for fallout from Indivior woes
Opioid maker sought drug group that treats abuse of its own painkillers
Grocer’s emphasis on loyalty scheme and app mirrors US giant’s ways
Consumer goods giant sheds £3bn in market value over potential exposure to opioid charges
UK-listed drugmaker vows to contest allegations as shares fall more than 70%
Drugmaker unable to provide 2019 guidance as it pursues last-ditch attempt to block rivals
UK Edition
